Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study
Morgan Roupret, Paolo Gontero, Stuart R C McCracken, Tim Dudderidge, Jacqueline Stockley, Ashleigh Kennedy, Oscar Rodriguez, Caroline Sieverink, Felicien Vanié, Marco Allasia, J Alfred Witjes, Marc Colombel, Richard Sylvester, Fabrizio Longo, Emanuele Montanari, Joan Palou, Morgan Roupret, Paolo Gontero, Stuart R C McCracken, Tim Dudderidge, Jacqueline Stockley, Ashleigh Kennedy, Oscar Rodriguez, Caroline Sieverink, Felicien Vanié, Marco Allasia, J Alfred Witjes, Marc Colombel, Richard Sylvester, Fabrizio Longo, Emanuele Montanari, Joan Palou
Abstract
Purpose: Detection of MCM5 containing cells in urine has been shown to be indicative of the presence of a bladder tumor on primary diagnosis. In this study we evaluate diagnostic performance of ADXBLADDER in patients undergoing cystoscopic surveillance in nonmuscle invasive bladder cancer followup.
Materials and methods: A multicenter prospective blinded study was performed at 21 European centers with patients undergoing cystoscopy for nonmuscle invasive bladder cancer surveillance, diagnosed in the preceding 2 years. Urine was collected from all eligible patients and ADXBLADDER-MCM5 testing was performed. Performance characteristics were calculated by comparing MCM5 results to the outcome of cystoscopy plus pathological assessment.
Results: Of 1,431 eligible patients enrolled 127 were diagnosed with a bladder cancer recurrence. The overall sensitivity for the ADXBLADDER-MCM5 test in detecting bladder cancer recurrence was 44.9% (95% CI 36.1-54) with a 75.6% sensitivity for nonpTaLG tumors (95% CI 59.7-87.6). Specificity was 71.1% (95% CI 68.5-73.5). The overall negative predictive value was 93% (95% CI 91.2-94.5). However, ADXBLADDER was able to rule out the presence of a nonpTaLG recurrent tumor with a negative predictive value of 99.0% (95% CI 98.2-99.5). No statistically significant differences in the performance of ADXBLADDER were observed as a result of age or sex.
Conclusions: This large blinded prospective study demonstrates that in the followup of patients with nonmuscle invasive bladder cancer ADXBLADDER is able to exclude the presence of the most aggressive tumors with a negative predictive value of 99%. These results indicate that ADXBLADDER could be incorporated in the followup strategy of nonmuscle invasive bladder cancer.
Keywords: MCM5 protein.; biomarkers; urinary bladder neoplasms; watchful waiting.
Source: PubMed